Acceleration of tumor growth due to dysfunction in M1 macrophages and enhanced angiogenesis in an animal model of autoimmune disease

Laboratory Investigation

Volumn 96, Issue 4, 2016, Pages 468-480

  Kondo, Tomoyuki ^a   Tsunematsu, Takaaki ^a   Yamada, Akiko ^a   Arakaki, Rieko ^a   Saito, Masako ^a   Otsuka, Kunihiro ^a   Kujiraoka, Satoko ^a   Ushio, Aya ^a   Kurosawa, Mie ^a   Kudo, Yasusei ^a   Ishimaru, Naozumi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN; PROTEIN ARG 1; PROTEIN FIZZ 1; PROTEIN YM1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; COLONY STIMULATING FACTOR 1; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CANCER TISSUE; COCULTURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MELANOMA B16; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VASCULARIZATION; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CLASSIFICATION; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; AUTOIMMUNE DISEASES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; MICE, INBRED MRL LPR; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84962227687     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2015.166     Document Type: Article

References (54)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
2. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013;39:61-73.
3. Darcy PK, Neeson P, Yong CS et al. Manipulating immune cells for adoptive immunotherapy of cancer. Curr Opin Immunol 2014;27: 46-52.
4. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014;41:49-61.
5. Biswas SK, Chittezhath M, Shalova IN et al. Macrophage polarization and plasticity in health and disease. Immunol Res 2012;53:11-24.
6. Mantovani A, Biswas SK, Galdiero MR et al. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 2013;229: 176-185.
7. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010;32:593-604.
8. Mantovani A, Sozzani S, Locati M et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-555.
9. Morel L. Genetics of SLE: evidence from mouse models. Nat Rev Rheumatol 2010;6:348-357.
10. Kobezda T, Ghassemi-Nejad S, Mikecz K et al. Of mice and men: how animal models advance our understanding of T-cell function in RA. Nat Rev Rheumatol 2014;10:160-170.
11. Klareskog L, Padyukov L, Lorentzen J et al. Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat Clin Pract Rheumatol 2006;2:425-433.
12. Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nat Rev Rheumatol 2011;7:569-578.
13. Ayoub S, Hickey MJ, Morand EF. Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis. Nat Clin Pract Rheumatol 2008;4:98-105.
14. Poon IK, Lucas CD, Rossi AG et al. Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol 2014;14:166-180.
15. Moreno M, Bannerman P, Ma J et al. Conditional ablation of astroglial CCL2 suppresses CNS accumulation of M1 macrophages and preserves axons in mice with MOG peptide EAE. J Neurosci 2014;34:8175-8185.
16. Iwasa A, Arakaki R, Honma N et al. Aromatase controls Sjogren syndrome-like lesions through monocyte chemotactic protein-1 in target organ and adipose tissue-associated macrophages. Am J Pathol 2015;185:151-161.
17. Azizi G, Malchoff CD. Autoimmune thyroid disease: a risk factor for thyroid cancer. Endocr Pract 2011;17:201-209.
18. Bernatsky S, Ramsey-Goldman R, Labrecque J et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 2013;42:130-135.
19. Bin J, Bernatsky S, Gordon C et al. Lung cancer in systemic lupus erythematosus. Lung Cancer 2007;56:303-306.
20. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-2344.
21. Cillo C, Dick JE, Ling V et al. Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines. Cancer Res 1987;47: 2604-2608.
22. Dong Z, Yoneda J, Kumar R et al. Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor. J Exp Med 1998;188:755-763.
23. Oura R, Arakaki R, Yamada A et al. Induction of rapid T cell death and phagocytic activity by Fas-deficient lpr macrophages. J Immunol 2013;190:578-585.
24. Collet G, El Hafny-Rahbi B, Nadim M et al. Hypoxia-shaped vascular niche for cancer stem cells. Contemp Oncol (Pozn) 2015;19:A39-A43.
25. Smitten AL, Simon TA, Hochberg MC et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.
26. Bernatsky S, Ramsey-Goldman R, Rajan R et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005;64: 1507-1509.
27. Dias C, Isenberg DA. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol 2011;7:360-368.
28. Sonoki T, Tatetsu H, Nagasaki A et al. Molecular cloning of translocation breakpoint from der(8)t(3;8)(q27;q24) defines juxtaposition of downstream of C-MYC and upstream of BCL6. Int J Hematol 2007;86:196-198.
29. Spehalski E, Kovalchuk AL, Collins JT et al. Oncogenic Myc translocations are independent of chromosomal location and orientation of the immunoglobulin heavy chain locus. Proc Natl Acad Sci USA 2012;109:13728-13732.
30. Boussios S, Pentheroudakis G, Somarakis G et al. Cancer diagnosis in a cohort of patients with Sjogren's syndrome and rheumatoid arthritis: a single-center experience and review of the literature. Anticancer Res 2014;34:6669-6676.
31. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010;127:759-767.
32. Wei WZ, Jacob JB, Zielinski JF et al. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. Cancer Res 2005;65:8471-8478.
33. Melero I, Hervas-Stubbs S, Glennie M et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7: 95-106.
34. Mantovani A, Allavena P, Sica A et al. Cancer-related inflammation. Nature 2008;454:36-44.
35. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
36. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-612.
37. Bottazzi B, Walter S, Govoni D et al. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol 1992;148:1280-1285.
38. Sica A, Saccani A, Bottazzi B et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol 2000;164:762-767.
39. Biswas SK, Gangi L, Paul S et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006;107: 2112-2122.
40. Hagemann T, Lawrence T, McNeish I et al. 'Re-educating' tumorassociated macrophages by targeting NF-kappaB. J Exp Med 2008;205: 1261-1268.
41. Dong Z, Kumar R, Yang X et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88:801-810.
42. Li J, Hsu HC, Mountz JD. Managing macrophages in rheumatoid arthritis by reform or removal. Curr Rheumatol Rep 2012;14:445-454.
43. Baumann I, Kolowos W, Voll RE et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002;46: 191-201.
44. Perniok A, Wedekind F, Herrmann M et al. High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus 1998;7:113-118.
45. Hanayama R, Tanaka M, Miyasaka K et al. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 2004;304:1147-1150.
46. Hu CY, Wu CS, Tsai HF et al. Genetic polymorphism in milk fat globule-EGF factor 8 (MFG-E8) is associated with systemic lupus erythematosus in human. Lupus 2009;18:676-681.
47. Bloom RD, Florquin S, Singer GG et al. Colony stimulating factor-1 in the induction of lupus nephritis. Kidney Int 1993;43:1000-1009.
48. Kelley VE, Wing E. Loss of resistance to listeria infection in autoimmune MRL/lpr mice: protection by prostaglandin E1. Clin Immunol Immunopathol 1982;23:705-710.
49. Menke J, Rabacal WA, Byrne KT et al. Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis. J Am Soc Nephrol 2009;20:2581-2592.
50. Iwata Y, Bostrom EA, Menke J et al. Aberrant macrophages mediate defective kidney repair that triggers nephritis in lupussusceptible mice. J Immunol 2012;188:4568-4580.
51. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013;13:871-882.
52. Burke B, Tang N, Corke KP et al. Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxiaregulated cancer gene therapy. J Pathol 2002;196:204-212.
53. Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-1545.
54. Muraoka D, Kato T, Wang L et al. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells. J Immunol 2010;185:3768-3776.